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Vascular inﬂammation has been implicated in the progression of cardiovascular diseases such as atherosclerosis. In the present
study, we found that HMC05, an extract from eight diﬀerent herbal mixtures, dose-dependently inhibited tumor necrosis factor-
α (TNF-α)-induced adhesion of monocytes to endothelial cells. Such inhibitory eﬀect of HMC05 correlated with suppressed
expression of monocyte chemoattractant protein-1, CC chemokine receptor 2, vascular cell adhesion molecule-1 and intercellular
cell adhesion molecule-1. In addition, HMC05 signiﬁcantly inhibited production of reactive oxygen species (ROS) and nuclear
factor (NF)-κBa c t i v a t i o nb yT N F - α. Those inhibitory eﬀects of HMC05 (1–10μgmL −1)o nt h eT N F - α-induced inﬂammatory
event was similar to those of berberine (1–10μM), which is a major component of HMC05 and one of herbal compounds
known to have vasorelaxing and lipid-lowering activities. However, berberine signiﬁcantly reduced the viability of HUVECs in
a time- and concentration-dependent manner. In contrast, HMC05 (1–10μgml −1)d i dn o ta ﬀect the cell viability for up to 48h
treatment. In conclusion, we propose that HMC05 may be a safe and potent herbal formula against vascular inﬂammation,
and its action may be attributable to the inhibition of ROS- and NF-κB-dependent expression of adhesion molecules and
chemokines.
1.Introduction
Vascular endothelium plays a central role in modulating
the inﬂammatory response in a way that they attract in-
ﬂammatory cells, activate the coagulant and complement
systems and increase vascular permeability [1]. Activation
of endothelial cells by pro-inﬂammatory mediators express
increased level of adhesion molecules such as vascular cell
adhesion molecule-1 (VCAM-1), E-selectin and intercellular
cell adhesion molecule-1 (ICAM-1) and chemokines, which
facilitate adhesion of monocytes to endothelial cells [2,
3]. Such endothelial activation is one of the earliest and
important processes in the pathophysiology of vascular
diseases such as atherosclerosis and hypertension [4, 5].
Production of pro-inﬂammatory cytokines such as tumor
necrosis factor-α (TNF-α) can be stimulated by various
pathophysiological phenomena including modiﬁed low den-
sity lipoprotein (LDL) [6, 7], hemodynamic stress [8, 9]a n d
hypertension [10].
H M C 0 5i saw a t e re x t r a c to fe i g h th e r b a ld r u gm i x t u r e s
originated and modiﬁed from a popular traditional herbal
medicine, Banhabackchulchunmatang [11]. Previous studies
on each of herbal drug components have revealed protective
activities against atherosclerosis and inﬂammation through
promotion of anti-inﬂammatory mediator production [12,
13], and inhibition of peroxynitrite-induced oxidative dam-
age [14]. HMC05 has showed an anti-atherosclerotic activity
through inhibition of pro-inﬂammatory cytokine produc-
tion in a recent study with standardized HMC05 based
on berberine and hesperidine [15]. However, the eﬀects
of HMC05 on endothelial inﬂammatory response have
not been clearly demonstrated. In addition, previously, we
have shown that berberine, an alkaloid isolated from the
traditional Chinese herbal medicine, huanglian (Coptis chi-
nensis), exert a cytotoxic eﬀect on endothelial cells, whereas
a berberine-containing herbal formula, Zoagumhwan, does
not possess cytotoxicity on the cells [16]. HMC05, which
contains berberine as a major component, has not been2 Evidence-Based Complementary and Alternative Medicine
clearly demonstrated for its cytotoxicity proﬁle on endothe-
lial cells. Therefore, in the present study, we investigated the
eﬀectsofHMC05onTNF-α-inducedinﬂammatory response
and viability of endothelial cells in comparison to the eﬀect
of berberine alone.
2.Methods
2.1. Materials. Human umbilical vein endothelial cell line
(HUVEC) and the human premonocytic cell line U937
were purchased from Clonetics (San Diego, CA, USA)
and American Type Culture Collection (ATCC, VA, USA),
respectively. Endothelial growth medium (EGM)-2 bullet kit
which contains an endothelial cell basal medium (EBM)-2
and EGM-2 SingleQuots (supplements and growth factors)
were purchased from Cambrex (San Diego). Fetal bovine
serum (FBS) was obtained from Hyclone (Logan, UT,
USA), and penicillin and streptomycin were from Gibco
BRL (Rockville, MD, USA). 3-[4, 5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT), sodium pyruvate,
berberine, and 2 ,7 -dichlorodihydroﬂuorescein diacetate,
acetyl ester (DCF-DA) were from Sigma-Aldrich (St Louis,
MO, USA). Antibodies against NF-κB (p65) and lamin B
were purchased fromSanta CruzBiotechnology(Santa Cruz,
CA, USA). Mouse monoclonal antibodies (mAbs) against
human ICAM-1 and VCAM-1 were purchased from R&D
Systems (Minneapolis, MN, USA), and rabbit polyclonal
anti-CCR2 was from Abcam (Cambridge, UK).
2.2. Herbal Composition and Preparation of Water Extract
(HMC05). All the herbs used for HMC05, Pinelliae ternate
Ten. Ex Breitenb., Atractylodes macrocephala Koidz., Gastro-
dia elata Blume, Citrus unshiu Marcow., Poria cocos Wolf,
Crataegus pinnatiﬁda Bunge var. typica C. K. Schneider,
Siegesbeckia pubescens Makio. and Coptidis japonica Makino,
were purchased from oriental drug stores (Kyungdong herb
market, Seoul, Korea). The herbs were identiﬁed at the
Oriental Medical College, Dongguk University (Gyoungju,
Korea), where voucher specimen was preserved. The herbs
had a moisture content of <10% by weight. HMC05 was
extracted with 500ml of distilled water under reﬂux for 3h
by boiling the formula, ﬁltered with 10μm cartridge paper
a n dc o n c e n t r a t e dt oa b o u t5 0 m lw i t har o t a r ye v a p o r a t o r
at 50◦C under vacuum and freeze-dried to dryness. It was
standardized on the basis of berberine and hesperidine,
using HPLC under acetonitrile: 0.1% formic acid gradient
over a period of 25min: acetonitrile 0–10%, 0–10min; 10–
40%, 10–20min; 40–90%, 20–25min [15]. The content of
berberine and hesperidine in HMC05 was 1.93 ± 0.11% and
1.02 ± 0.11%, respectively.
2.3. Cell Culture. HUVECs were grown on 0.2% gelatin-
coated ﬂask with EBM-2 medium supplemented with 2%
FBS,ascorbic acid, hydrocortisone, human ﬁbroblast growth
factor, vascular endothelial growth factor, human epidermal
growth factor, long R insulin-like growth factor-1, gen-
tamicin sulfate (GA-1000) and heparin. HUVECs between
passage 2 and 6 were used in the experiments.
U937 cells were maintained in a RPMI 1640 medium
supplemented with 10% FBS, 1mM sodium pyruvate,
100IUml−1 penicillin and 100μgml −1 of streptomycin.
After attaining conﬂuence, the cells were subcultured by
s p l i t t i n g1:5r a t i o .
2.4. Measurement of Cell Viability. The cell viability was
assessed usingtheMTT staining method.Thecellsfrom4-to
5-day-old cultures were seeded in 96-well plates at a density
of 1 × 104 cells well−1. The volume of the medium in the
wells was 100μl. In the control experiments, the cells were
grown in the same media containing the drug-free vehicle.
The cells were incubated with the drug for 48h, and then
with 10μlo fM T T( 5gl −1) for 4h. Two hundred microliters
of dimethyl sulfoxide were added to each culture and mixed
by pipetting to dissolve the reduced MTT crystals. The
relative cell viability was determined by measuring optical
density in a microplate reader (Molecular Devices, Versa
MAX Sunnyvale, CA, USA) at 540 nm.
2.5. Fluorescent Labeling of U937 Cells and Cell Adhesion
Assay. U937 human premonocytic cells were used to inves-
tigate leukocyte-endothelial cell interaction [17], and these
cells are known to express CCR2, a receptor for MCP-1
[18]. U937 cells were labeled with 2 ,7 -bis(2-carboxyethyl)-
5(6)-carboxyﬂuorescein acethoxymethyl ester (BCECF/AM,
10μgml −1)f o r1 ha t3 7 ◦C. HUVECs cultured in 24-well
platewerepretreatedwithHMC05waterextractorberberine
for 30min and then incubated with TNF-α for an additional
3h. Then, HUVECs were co-incubated with BCECF/AM-
prelabeled U937 cells (1 × 106 cells well−1)f o r3 0 m i na t
37◦C. Non-adhering U937 cells were removed, and the cells
were washed twice with PBS. A set of cells was taken and
imaged by inverted microscopy connected to digital camera
(TMS; Nikon, Japan), and in other sets, cells were lysed
in 0.1% Triton X-100 in 0.1mol l−1 Tris. Fluorescence was
measured by using a Fluostar optima microplate reader
(BMG LABTECH GmbH, Germany) using excitation at 485
nm and emission at 520 nm.
2.6. Quantitative Real-Time Reverse Transcription Polymerase
Chain Reaction. Cells were collected and total RNA was
extracted with a spin column using RNeasy kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instruc-
tions. Isolated mRNA was reverse transcribed by using the
Reverse Transcription kit (Qiagen). The gene expression
levels were analyzed by quantitative real-time PCR system
(Rotor-Gene 6000; Corbett, Sydney, Australia). Real-time
PCR was performed using a SYBR Green PCR kit (Qiagen).
The primer sequences for MCP-1, CCR2, VCAM-1 and
ICAM-1 were as follows: MCP-1, sense 5 -TCGCGAGCT-
ATAGAAGAATC-3  and antisense 5 -AATCCTGAACCC-
ACTTCT-3 ; CCR2, sense 5 -CTGGTGTTCATCTTTGGT-
TT-3  and antisense 5 -CCCACAATGGGAGAGTAATA-
3 ;V C A M - 1 ,s e n s e5  -GGGAGCTCTGTCACTGTAAG-3 
and antisense 5 -ATCCGTATCCTCCAAAAACT-3 ;I C A M -
1, sense 5 -CCTTCCTCACCGTGTACTGG-3  and antisense
5 -AGCGTAGGGTAAGGTTCTTGC-3 .T h er e a c t i o nm i x -
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PCR master mix and 5pmol of primers in total volume of
20μl. The cDNA was denatured at 95◦C for 15min followed
by 40 cycles of PCR (95◦Cf o r5 s ,5 5 ◦C for 10s, 72◦C
for 20s). The mRNA levels of all genes were normalized
using glyseraldehyde-3-phosphate dehydrogenase GAPDH
(Qiagen) as an internal control.
2.7. Immunocytochemical Analysis for ICAM-1 and VCAM-1
Expression. The cellular localization of adhesion molecules,
ICAM-1 and VCAM-1, were examined by an immunocyto-
chemical method. HUVECs were cultured in sterile eight-
well chamberedslides(NalgeNuncInternational,Naperville,
IL,USA)with mediumaloneormediumcontainingHMC05
or vehicle for 1h before an additional 3h treatment of
TNF-α (10ngml−1). The cells were then ﬁxed with ice-cold
methanolfor 5min at −20◦C.Afterairdryingfor10min,the
slides were blocked with 3% bovine serum albumin (BSA)
for 1h and incubated with ICAM-1 or VCAM-1 monoclonal
antibody (1 : 20 dilution of a 200 μgml −1 solution) at 4◦C
overnight in humidiﬁed chamber. The cells were washed
three times with TBS-T (20mM Tris–HCl, pH 7.5, 500mM
NaCl, 0.1% Tween 20) for 5min and then incubated with
Alexa Fluor 488 donkey anti-mouse IgG (1 : 200) in TBS
with 3% BSA for 1h at room temperature. After washing in
TBS-T for 30min, the cells were stained with 600nM 4 ,6-
diamidino-2-phenyli n d o l e( D A P I )f o r2 m i n .A f t e rs e v e r a l
brief washings, the cells were mounted with Prolong Gold
Antifade reagent and covered with a coverslip. Finally, the
cells were observed using a Nikon microscope (TE-2000U)
with appropriate excitation/emission ﬁlter pairs.
2.8. Measurement of Intracellular Reactive Oxygen Species.
Intracellular reactive oxygen species (ROS) generation was
measured using 2 ,7 -dichloroﬂuorescein diacetate (DCF-
DA;Sigma),a ﬂuorescent dye. Conﬂuentcells were subjected
to serum starvation (0.5% FBS) for 24h and then used
for experiments. Starved cells were treated with HMC05 or
berberine in the presence of TNF-α (10ngml−1)f o r1 h .
The cells were loaded with DCF-DA (5μM) for 5min at
37◦C, and then, imaged by inverted ﬂuorescence microscopy
(TE2000-U; Nikon, Japan), and analyzed with an image
analysis system (ImageInside Ver 2.32).
2.9. Protein Extraction and Western Blot Analysis. Cells were
incubatedwith TNF-αinthepr es enc eorabs enc eofHMC05.
For the detection of NF-κBi nH U V E C s ,n u c l e a rp r o t e i n
extraction was carried out by using an NE-PER kit as per
manufacturer’s instructions (Pierce, Rockford, IL, USA). In
case of CCR2 detection, total proteins were extracted from
U937 cells using RIPA buﬀer containing protease inhibitor
cocktail (Sigma). Protein content was measured with BCA
protein assay reagent (Pierce). Equal amount of proteins
(20μgnuclearor70μgtotalproteins)were separatedon10%
SDS–PAGE and transferred to nitrocellulose membranes.
The membranes were blocked with 5% nonfat milk in TBS-
T for 2h, and incubated with speciﬁc antibodies in TBS
containing 1% non-fat milk at 4◦C overnight. After washing
threetimeswithTBS-T,themembraneswerehybridizedwith
horseradish peroxidase-conjugated secondary antibody in
skim-milk-TBSfor1hatroomtemperature.Theimmunore-
active proteins were visualized using an ECL kit.
2.10. NF-κB Reporter Gene Dual-Luciferase Assay. NF-κB
transactivation was studied by using NF-κBl u c i f e r a s e
reporter construct (ﬁreﬂy luciferase) in conjunction with
0.05μg/ml of pRL-TK (renilla luciferase as a transfection
control) using lipofectamine transfection reagent (Invitro-
gen, CA, USA) according to the manufacturer’s instructions.
HUVECs (1 × 105 cells well−1) were incubated with
transfection mixture at 37◦C for 5h, mixed with the same
volume of growth medium, and kept in an incubator at
37◦C overnight. These cells were then treated with HMC05
or BER in the presence of 10ngml−1 TNF-α.A f t e r3 h ,
the cells were washed with PBS and then lysed by repeated
freezing and thawing. Cells were then scraped gently and
the lysates were centrifuged at 10000rpm for 5min. Fireﬂy
and renilla luciferase activities were measured using Dual-
Luciferase Reporter Assay Kit (Promega Corporation, Madi-
son, WI, USA) on a Turner TD20/20 luminometer (Turner
Biosystems, CA, USA).
2.11. Statistical Analysis. The data are expressed as mean
± standard error of mean (SEM) of more than three
independent experiments and were analyzed using one-way
analysis of variance (ANOVA)and the Student—Newman—
Keul’s test for individual comparisons. P values of < .05 were
considered statistically signiﬁcant.
3.Results
3.1. HMC05 Inhibits Monocyte Adhesion to Endothelial Cells
Induced by oxLDL and TNF-α. We ﬁrst examined the eﬀect
of HMC05 on the oxidized LDL (oxLDL)-induced vascular
inﬂammation by measuring the adhesion of inﬂammatory
leukocytesto endothelial cells, a crucial step ininﬂammatory
process. As shown in Figure 1(a),H M C 0 5i n h i b i t e do x L D L -
induced adhesion of leukocytes to HUVECs. Since in a
variety of vascular diseases including atherosclerosis, TNF-α
levelis increased in the lesion site and contributesto vascular
inﬂammatory process [19, 20], we then examined the eﬀect
ofHMC05onTNF-α-treatedendothelialresponse. HUVECs
stimulated with TNF-α (10ngml−1)f o r3 hs i g n i ﬁ c a n t l y
increasedadhesionofleukocytestotheendothelialcellscom-
pared with untreated (control) cells (Figures 1(b) and 1(c)).
The TNF-α-induced adhesion was signiﬁcantly inhibited by
H M C 0 5( 1a n d1 0 μgml −1) in a concentration-dependent
manner. The inhibitory activity of HMC05 (1–10μgml −1)
on TNF-α-induced adhesion of monocytes to HUVECs was
similar to those of berberine (1–10μM), a major component
of HMC05, or simvastatin (5μM), a hypolipidemic and
cardiovascular risk-reducing drug.
3.2. Inhibitory Eﬀects of HMC05 on TNF-α-Induced Expres-
sion of Chemokine, MCP-1 and Adhesion Molecules, VCAM-
1 and ICAM-1, in HUVECs. The increased expression of
chemokines and cell adhesion molecules on endothelial cells4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Inhibitory eﬀects of HMC05 and berberine on oxLDL- andTNF-α-induced monocyte adhesion to endothelialcells. The adhesion
of ﬂuorescence-labeled U937 cells to HUVECs was detected by microscopic images ((a) and (b)), and quantitated by using a ﬂuorescence-
detecting microplate reader (c). HUVECs were pretreated with diﬀerent concentrations of HMC05 (1 and 10μgml −1), simvastatin (5μM)
or berberine (1 and 10μM) for 30min before oxLDL (50μgml −1)a n dT N F - α (10ngml−1) treatment for 3h. Data are expressed as the
mean ± SEM of three independent experiments with duplicates. ∗P < .01 compared with untreated control group. #P < .01 compared with
TNF-α-treated group.Evidence-Based Complementary and Alternative Medicine 5
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Figure 2: Inhibitory eﬀects of HMC05 and berberine on TNF-α-induced mRNA expression of MCP-1, VCAM-1 and ICAM-1 in HUVECs.
Serum-starved HUVECs were treated with HMC05 and berberine in the absence ((a) and (b)) or presence (c–e) of TNF-α (10ngml−1).
After 3h,the cells were harvested, and the mRNA expression ofMCP-1 ((a)and (c)),VCAM-1 ((b) and (d)) and ICAM-1 (e) wasquantiﬁed
by real-time RT-PCR. Data are expressed as the mean ± SEM of four independent experiments with duplicates. ∗P < .05 compared with
untreated control group. #P < .05 compared with TNF-α-treated group.
promotes the adhesion of leukocytes, which is regarded as
the molecular basis for the inﬂammatory response observed
in various diseases [20–22]. Real-time reverse transcription
polymerase chain reaction (RT–PCR) was carried out to
examine the eﬀects of HMC05 on the mRNA expression
of MCP-1, one of the key factors to initiate inﬂammatory
process in vascular inﬂammation, and adhesion molecules,
VCAM-1 and ICAM-1. Treatmentof HUVECs with TNF-α
increased MCP-1 (Figure 2(a))a n dV C A M - 1( Figure 2(b))
mRNA level in a time-dependent manner. Treatment with
HMC05 concentration-dependently suppressed the TNF-α-
inducedmRNAexpressionofMCP-1(Figure 2(c)),VCAM-1
(Figure 2(d))andICAM-1(Figure 2(e)).Similarly,berberine
treatmentalsoinhibitedtheTNF-α-inducedMCP-1,VCAM-
1 and ICAM-1 mRNA expressions. The degree of reduction
in VCAM-1 expression by HMC05 (10μgml −1)w a ss i m i l a r6 Evidence-Based Complementary and Alternative Medicine
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Figure3:Inhibitoryeﬀects ofHMC05andberberine onTNF-α-induced proteinexpressionofadhesionmolecules,VCAM-1(a)andICAM-
1 (b), in HUVECs. Serum-starved HUVECs were treated with HMC05 and berberine in the absence or presence of TNF-α (10ngml−1)f o r
3h. After ﬁxation with methanol, immunocytochemical analysis was performed as described in ‘Materials and methods’ section. The result
shown is a representative of three independent experiments.
to the eﬀect of berberine (10μM), whereas suppression of
MCP-1 and ICAM-1 expression by HMC05 was stronger
than by berberine. To further assess the eﬀect of HMC05 on
protein expression of the adhesion molecules, immunocy-
tochemistry were performed. As shown in Figures 3(a) and
3(b), VCAM-1 and ICAM-1 protein expression levels were
high in TNF-α-stimulated HUVECs, which was suppressed
by HMC05 and berberine treatment.
3.3. CCR2 Expression in TNF-α-treated Human Monocytic
U937 Cells Was Inhibited by HMC05. Since MCP-1 binds
only to CCR2 [23], the expression of CCR2 plays an
important role in monocyte recruitment and in many
inﬂammatory states of vessels. The CCR2 mRNA expression
was increased by the treatment with TNF-α for 3h in
U937 cells, but this eﬀect was signiﬁcantly inhibited by
co-treatment with HMC05 (10μgml −1)( Figure 4(a)). The
eﬀect of berberine (10μM) on the TNF-α-induced CCR2
expression was similar to that of HMC05. Similarly, we
also noted the protein expression of CCR2 in U937 cells
was increased by TNF-α in a western blot analysis, which
upon HMC05 treatment, signiﬁcantly downregulated in a
concentration-dependent manner (Figure 4(b)).
3.4. Geranylgeranyl Pyrophosphate Reverses the Inhibitory
Activity of HMC05 on TNF-α-Induced ROS Increase. SinceEvidence-Based Complementary and Alternative Medicine 7
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Figure 4: Inhibitory eﬀects of HMC05 and berberine on TNF-α-
induced CCR2 mRNA (a) and protein expression (b) in U937 cells.
Serum-starved cells were treated with HMC05 and berberine in the
presence ofTNF-α for3h.CCR2 mRNAlevelwasexaminedbyreal-
time RT–PCR (a), and the data are expressed as the mean ± SEM
of four independent experiments with duplicates. CCR2 protein
expression was examined by western blot analysis (b). The blot
is a representative of three independent experiments, and the bar
graphs represent relative density of CCR2/Actin. Data are expressed
as the mean ± SEM of three independent experiments. ∗P < .01
compared with untreated control group. #P < .01 compared with
TNF-α-treated group.
TNF-α increases ROS production which is a major cause of
vascular inﬂammation, we examined the eﬀect of HMC05
on TNF-α-induced ROS increase by measuring DCF ﬂuo-
rescence using a microﬂuorometry. Co-treatment of the cells
with HMC05 and TNF-α signiﬁcantly inhibited the TNF-
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Figure 5: HMC05 suppresses TNF-α-induced geranylgeranyl
isoprenoid-dependent ROS generation. HUVECs were treated with
TNF-α in the presence or absence of HMC05 and/or GGPP for
1h, and incubated with DCF-DA (5μM) for an additional 5min.
The intensity of DCF ﬂuorescence detecting intracellular ROS was
analyzed by using ImageInside program. Data are expressed as the
mean ±SEMofthree independent experiments. ∗P <.01compared
with untreated control group. #P < .01 compared with the TNF-α-
treated group. $P < .01 compared with TNF-α and HMC05-treated
group.
α-induced ROS production (Figure 5). Similarly, treatment
with berberine also suppressed the TNF-α-induced ROS
increase. It is well known that TNF-α-induced ROS increase
in endothelial cells is associated with activation of NADPH
oxidase through prenylation of Rac1 by geranylgeranyl
pyrophosphate (GGPP) [24–26]. To assess the involvement
of NADPH oxidase through Rac prenylation in TNF-
α-induced ROS production, we examined the eﬀects of
exogenous application of GGPP. The pretreatment with
exogenously applied GGPP in combination with HMC05
completely reversed the inhibitory eﬀects of HMC05 on
TNF-α-induced ROS generation (Figure 5).
3.5. Suppression of NF-κB Transcriptional Activity by HMC05
in HUVECs Treated with TNF-α. NF-κBi saw e l l - k n o w n
redox-sensitive transcription factor of various proinﬂam-
matory genes including cell adhesion molecules [22]. TNF-
α-induced nuclear NF-κB p65 accumulation (Figure 6(a))
was signiﬁcantly suppressed by HMC05 and berberine
(Figure 6(b)). Furthermore, in the cells transfected with NF-
κB-Luc plasmid (Figure 6(c)), TNF-α-stimulated increase
in NF-κB transcriptional activity was inhibited by HMC05
in a concentration-dependent manner. Such eﬀect of
HMC05 (1μgml −1)w a ss i m i l a rt ot h a to fb e r b e r i n e
(10μM).
3.6. Diﬀerential Eﬀects of HMC05 and Berberine on the
Viability of HUVECs. To examine whether treatment of
the cells with HMC05 aﬀects viability of endothelial cells,
HUVECs were treated with HMC05 or berberine in a dif-
ferent time- and concentration-scale. As shown in Figure 7,
HMC05 treatment had no adverse eﬀect on the viability8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Inhibitory eﬀects of HMC05 and berberine on TNF-α-
induced NF-κB activation in HUVECs. The cells were incubated
with TNF-α alone for the designated time (a), or in the presence of
HMC05 and berberine for 3h (b). The nuclear extracts (20μgp r o -
tein) were separated on SDS–PAGE, transferred to a nitrocellulose
membrane, and blotted with the anti-NF-κB p65 subunit antibody.
The blots are a representative of three independent experiments,
and the bar graphs represent relative density of NF-κB/Lamin B.
(c) After HUVECs were transfected with NF-κB luciferase (ﬁreﬂy)
construct together with pRL-TK (renilla luciferase), the cells were
stimulated with TNF-α in the presence or absence of HMC05
or berberine. Luciferase activities were determined using a dual-
luciferase reporter assay kit and normalized to those of control
values. The data shown are mean ± SEM of three independent
experiments. ∗P < .05 compared with untreated control group. #P
< .05 compared with the TNF-α-treated group.
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Figure 7: Eﬀects of HMC05 and berberine on the viability
of HUVECs. Cells were treated with diﬀerent concentration of
HMC05andberberine fortheindicatedtime,andthen,cell viability
wasmeasured by MTTassay.Thedata are shownasmean ± SEMof
three independent experiments with triplicates. ∗P < .01 compared
with untreated control group.
of HUVECs (>95% cell viability). In contrast, berberine
signiﬁcantly reduced the viability of HUVECs in a time- and
concentration-dependent manner.
4.Discussion
Pro-inﬂammatory cytokinesare thoughttobe centralplayers
in the development of vascular inﬂammation, which leads
to the development of cardiovascular complications [27,
28]. TNF-α, a commonly found cytokine in atherosclerotic
lesions, induces cell adhesion molecules, which contribute
to the inﬂammatory process [20]. In addition, it has been
highlighted that cytokine-activated endothelial cells secrete
monocyte-speciﬁc chemoattractant molecules to recruit
monocytes at the sites of vascular injury and inﬂammation
[29].
The present study clearly showed that HMC05 sig-
niﬁcantly inhibited oxLDL-and TNF-α-induced monocyte
adhesion onto endothelial cells in along with reduced
expressions of MCP-1, VCAM-1 and ICAM-1 in HUVECs.
In addition, HMC05 also blocked the TNF-α-increased
expression of CCR2, the MCP-1 receptor, in monocytes.
Since the MCP-1/CCR2 binding is the major regulator of
monocyte recruitment and seems to play a primary role in
many inﬂammatory states of vessels, our results suggest that
HMC05 is an eﬀective formula for vascular inﬂammation by
suppressing both the expression of endothelial chemokine
and monocyte chemokine receptors.
Oxidative stress is a characteristic feature of the vas-
cular inﬂammatory response and in the pathogenesis of
atherosclerosis [30]. The expression of adhesion molecules
on the endothelial cell surface during primary inﬂammatoryEvidence-Based Complementary and Alternative Medicine 9
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Figure 8: Schematic diagram showing signaling pathway HMC05 action against TNF-α-induced vascular inﬂammation. HMC05 may
protect vascular inﬂammation through suppression of ROS production and the expression of NF-κB-related adhesion molecules in
endothelial cells, which in turn, prevents monocyte adhesion to endothelial cells. TNFR: tumor necrosis factor-α receptor. The solid arrow
and broken arrow represent activation, and migration, respectively.
response is dependent on the ROS-sensitive nuclear tran-
scription factor NF-κB and AP-1 activation [2, 31–33]. Our
results showing that HMC05 inhibited TNF-α-induced ROS
and NF-κB translocation indicate that inhibitory eﬀect of
HMC05 on TNF-α-induced monocyte adhesion to endothe-
lial cells is possibly mediated through suppression of ROS
and subsequent NF-κBa c t i v a t i o n .
Most importantly, our results clearly showed the diﬀer-
ence between HMC05 and berberine, a major component of
HMC05. The inhibitory eﬀectsof HMC05 on the monocyte-
endothelial adhesion were similar to those of berberine,
whereas HMC05 did not aﬀect the cell viability in contrast
to berberine. Although berberine is known to have lipid-
lowering eﬀect, and vasorelaxing activities as well as amelio-
rating the cardiovascular diseases such as hypertension and
atherosclerosis [34–36], recent study revealed that berberine
caused prothrombotic eﬀects on endothelial cells, indicating
the limitation on therapeutic application of berberine as
a monotherapy [37]. Furthermore, the cytotoxic property
of berberine is the most important and frequently tested
biological activity [38]. Similar to the previous reports, in
the present study, berberine showed signiﬁcant cytotoxicity
in HUVECs. However, HMC05 did not show any cytotoxic
eﬀect on HUVECs, suggesting that berberine-containing
HMC05 may be a safer remedy in the treatment of vascular
inﬂammation than berberine alone. Although we had not
determined the amount and activity of exact component,
HMC05 contains high levels of phenolic compounds that
have wide range of biological activities including antiox-
idant eﬀects. Recently, the main components of HMC05
were screened and identiﬁed as one ﬂavonoid, hesperidin
and three alkaloids, coptisine, palmatine and berberine
by simultaneous determination method [39]. For example,
hesperidin, one of the major components of HMC05, is
also reported to have many biological eﬀects including anti-
inﬂammatory, antimicrobial, anticarcinogenic, antioxidant
and radioprotective eﬀects [40, 41]. Based on those reports,
the reduced cytotoxicity of HMC05 compared with berber-
ine alone may possibly be due to the compensating action of
ﬂavonoid, hesperidin, against cytotoxic nature of berberine.
In conclusion, our results indicate that HMC05 may
protect vascular inﬂammation through suppression of ROS
production and regulation of the expression of NF-κB-
related adhesion molecules in endothelial cells (Figure 8).
Funding
Korea Health 21 R&D Project, Ministry of Health & Welfare,
Republic of Korea (grant no B080031) and the Regional
Technology Innovation Program of the Ministry of Com-
merce, Industry and Energy (MOCIE) (grant no RTI04-01-
04).
References
[1] P. Libby, “Inﬂammation in atherosclerosis,” Nature, vol. 420,
no. 6917, pp. 868–874, 2002.10 Evidence-Based Complementary and Alternative Medicine
[2] T. Collins, “Biology of disease: endothelial nuclear factor-κB
and the initiation of the atherosclerotic lesion,” Laboratory
Investigation, vol. 68, no. 5, pp. 499–508, 1993.
[3] M. I. Cybulsky and M. A. Gimbrone Jr., “Endothelial expres-
sion of a mononuclear leukocyte adhesion molecule during
atherogenesis,” Science, vol. 251, no. 4995, pp. 788–791, 1991.
[ 4 ]E .M .A .M e r v a a l a ,D .N .M¨ uller, J.-K. Park et al., “Monocyte
inﬁltration and adhesion molecules in a rat model of high
human renin hypertension,” Hypertension,v o l .3 3 ,n o .1 ,p p .
389–395, 1999.
[5] B.
￿sterud andE.Bjørklid,“Roleofmonocytes inatherogene-
sis,” Physiological Reviews, vol. 83, no. 4, pp. 1069–1112, 2003.
[6] J .A .Be r line r ,D .S.Sc h wart z,M.C .T e rrit oe tal. ,“ I nd u c t ionof
chemotactic cytokines by minimally oxidized LDL,” Advances
in Experimental Medicine and Biology, vol. 351, pp. 13–18,
1993.
[7] J. Hulthe and B. Fagerberg, “Circulating oxidized LDL is
associated with subclinical atherosclerosis development and
inﬂammatory cytokines (AIR study),” Arteriosclerosis, Throm-
bosis, andVascular Biology,vol.22,no.7,pp. 1162–1167,2002.
[8] A. V. Sterpetti, A. Cucina, A. R. Morena et al., “Shear stress
increases the release of interleukin-1 and interleukin-6 by
aortic endothelial cells,” Surgery, vol. 114, no. 5, pp. 911–914,
1993.
[9] K. Sakai, M. Akima, and I. Katsuyama, “Eﬀects of nicorandil
onexperimentally induced gastriculcers inrats:apossiblerole
of K(ATP) channels,” Japanese Journal of Pharmacology,v o l .
79, no. 1, pp. 51–57, 1999.
[10] M. Humbert, G. Monti, F. Brenot et al., “Increased
interleukin-1 and interleukin-6 serum concentrations in
severe primary pulmonary hypertension,” American Journal
of Respiratory and Critical Care Medicine, vol. 151, no. 5, pp.
1628–1631, 1995.
[ 1 1 ]H . - M .S h i na n dK .G .M o r g a n ,“ V a s o d i l a t i o nb ybanhab-
ackchulchunmatang, a Chinese medicine, is associated with
negative modulationof PKCα activation andNO production,”
Life Sciences, vol. 74, no. 6, pp. 723–732, 2003.
[12] N. P. Visavadiya and A. V. R. L. Narasimhacharya, “Aspara-
gus root regulates cholesterol metabolism and improves
antioxidant status in hypercholesteremic rats,” Evidence-Based
Complementary and Alternative Medicine,v o l .6 ,n o .2 ,p p .
219–226, 2009.
[13] L.Zhao ,J . - Y .T ao ,S. - L.Zhang,F .J in,R .P ang,andJ . - H .D ong,
“N-butanolextract frommelilotus suaveolensLedebaﬀectspro-
and anti-inﬂammatory cytokines and mediators,” Evidence-
Based Complementary and Alternative Medicine,v o l .7 ,n o .1 ,
pp. 97–106, 2010.
[ 1 4 ]T .Y o k o z a w a ,A .S a t o h ,E .J .C h o ,Y .K a s h i w a d a ,a n dY .
Ikeshiro,“Protective role ofCoptidis Rhizomaalkaloidsagainst
peroxynitrite-induced damage to renal tubular epithelial
cells,” Journal of Pharmacy and Pharmacology, vol. 57, no. 3,
pp. 367–374, 2005.
[15] K. M. Kim, J. Y. Choi, S.-E. Yoo et al., “HMCO5, herbal
extract, inhibits NF-κB expression in lipopolysaccharide
treated macrophages and reduces atherosclerotic lesions in
cholesterol fed mice,” Journal of Ethnopharmacology, vol. 114,
no. 3, pp. 316–324, 2007.
[ 1 6 ] Y .J .K o ,J . - S .L e e ,B .C .P a r k ,H .M .S h i n ,a n dJ . - A .
Kim, “Inhibitory eﬀects of Zoagumhwan water extract and
berberine on angiotensin II-induced monocyte chemoattrac-
tant protein (MCP)-1 expression and monocyte adhesion to
endothelial cells,” Vascular Pharmacology, vol. 47, no. 2-3, pp.
189–196, 2007.
[17] D. Carvalho, C. O. S. Savage, C. M. Black, and J. D.
Pearson, “IgG antiendothelial cell autoantibodies from scle-
roderma patients induce leukocyte adhesion to human
vascular endothelial cells in vitro: induction of adhesion
molecule expression and involvementofendothelium-derived
cytokines,” Journal of Clinical Investigation,v o l .9 7 ,n o .1 ,p p .
111–119, 1996.
[ 1 8 ]D .A .L a z z a r i n o ,M .D eD i e g o ,S .Z .H i r s c h m a ne ta l . ,“ I L -
8 and MCP-1 secretion is enhanced by the peptide-nucleic
acidimmunomodulator,product R,inU937cells andprimary
human monocytes,” Cytokine, vol. 14, no. 4, pp. 234–239,
2001.
[19] T. J.Reape and P. H. E. Groot, “Chemokines and atherosclero-
sis,” Atherosclerosis, vol. 147, no. 2, pp. 213–225, 1999.
[20] R. Ross, “Atherosclerosis-an inﬂammatory disease,” The New
England Journal of Medicine, vol. 340, pp. 115–126, 1999.
[21] D. T. Price and J. Loscalzo, “Cellular adhesion molecules and
atherogenesis,” American Journal of Medicine, vol. 107, no. 1,
pp. 85–97, 1999.
[22] C. K. Glass and J. L. Witztum, “Atherosclerosis: the road
ahead,” Cell, vol. 104, no. 4, pp. 503–516, 2001.
[ 2 3 ]L .B o r i n g ,J .G o s l i n g ,M .C l e a r y ,a n dI .F .C h a r o ,“ D e c r e a s e d
lesion formation in CCR2(-/-) mice reveals a role for
chemokines in the initiation of atherosclerosis,” Nature,v o l .
394, no. 6696, pp. 894–897, 1998.
[ 2 4 ]Y . - S .K i m ,M .J .M o r g a n ,S .C h o k s i ,a n dZ . - G .L i u ,“ T N F -
induced activation of the Nox1 NADPH oxidase and its role
in the induction ofnecrotic cell death,” Molecular Cell, vol.26,
no. 5, pp. 675–687, 2007.
[25] T. Vanden Berghe, W. Declercq, and P. Vandenabeele,
“NADPH oxidases: new players in TNF-induced necrotic cell
death,” Molecular Cell, vol. 26, no. 6, pp. 769–771, 2007.
[26] S.-Y. Park, J.-S. Lee, Y. J. Ko et al., “Inhibitory eﬀect
of simvastatin on the TNF-α- and angiotensin II-induced
monocyte adhesion to endothelial cells is mediated through
the suppression of geranylgeranyl isoprenoid-dependent ROS
generation,” Archives of Pharmacal Research,v o l .3 1 ,n o .2 ,p p .
195–204, 2008.
[27] L. Br˚ an´ en, L. Hovgaard, M. Nitulescu, E. Bengtsson, J.
Nilsson, and S. Jovinge, “Inhibition of tumor necrosis factor-
α reduces atherosclerosis in apolipoprotein E knockout mice,”
Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no.
11, pp. 2137–2142, 2004.
[28] H. Ohta,H.Wada,T. Niwa et al.,“Disruption oftumornecro-
sis factor-α gene diminishes the development of atherosclero-
sis in ApoE-deﬁcient mice,” Atherosclerosis, vol. 180, no. 1, pp.
11–17, 2005.
[29] B.J.Rollins,“Monocytechemoattractantprotein 1:apotential
regulator of monocyte recruitment in inﬂammatory disease,”
Molecular Medicine Today, vol. 2, no. 5, pp. 198–204, 1996.
[30] H. Cai and D. G. Harrison, “Endothelial dysfunction in
cardiovascular diseases: the role of oxidant stress,” Circulation
Research, vol. 87, no. 10, pp. 840–844, 2000.
[31] A. S. Neish, A. J. Williams, H. J. Palmer, M. Z. Whitley,
and T. Collins, “Functional analysis of the human vascular
cell adhesion molecule 1 promoter,” Journal of Experimental
Medicine, vol. 176, no. 6, pp. 1583–1593, 1992.
[ 3 2 ]K .Y .S t o k e s ,E .C .C l a n t o n ,J .M .R u s s e l l ,C .R .R o s s ,a n d
D. N. Granger, “NAD(P)H oxidase-derived superoxide medi-
ates hypercholesterolemia-induced leukocyte-endothelial cell
adhesion,” Circulation Research, vol. 88, no. 5, pp. 499–505,
2001.Evidence-Based Complementary and Alternative Medicine 11
[33] D. Cooper, K. Y. Stokes, A. Tailor, and D. N. Granger, “Oxida-
tive stress promotes blood cell-endothelial cell interactions in
the microcirculation,” Cardiovascular Toxicology,v o l .2 ,n o .3 ,
pp. 165–180, 2002.
[34] H.-S. Cui, S. Hayasaka, X.-Y. Zhang, Y. Hayasaka, Z.-L. Chi,
and L.-S. Zheng, “Eﬀect of berberine on interleukin 8 and
monocytechemotactic protein 1expression inahumanretinal
pigment epithelial cell line,” Ophthalmic Research, vol. 38, no.
3, pp. 149–157, 2006.
[ 3 5 ]C . - W .L a u ,X . - Q .Y a o ,Z . - Y .C h e n ,W . - H .K o ,a n dY .H u a n g ,
“Cardiovascular actions of berberine,” Cardiovascular Drug
Reviews, vol. 19, no. 3, pp. 234–244, 2001.
[36] W. Kong, J. Wei, P. Abidi et al., “Berberine is a novel
cholesterol-lowering drug working through a unique mech-
anism distinct from statins,” Nature Medicine, vol. 10, no. 12,
pp. 1344–1351, 2004.
[37] E. W. Holy, A. Akhmedov, T. F. L¨ uscher, and F. C. Tanner,
“Berberine, a natural lipid-lowering drug, exerts prothrom-
botic eﬀects on vascular cells,” Journal of Molecular and
Cellular Cardiology, vol. 46, no. 2, pp. 234–240, 2009.
[38] L. Grycov´ a, J. Dost´ al, and R. Marek, “Quaternary protober-
berine alkaloids,” Phytochemistry, vol. 68, no. 2, pp. 150–175,
2007.
[39] S. H. Kim, E. J. Choi, K. Y. Lee, S. H. Sung, and H.-M. Shin,
“Simultaneous determination of alkaloids and ﬂavonoids
in HMC05 preparation by HPLC-DAD,” Journal of Liquid
Chromatography and Related Technologies, vol. 31, no. 19, pp.
2917–2926, 2008.
[40] A. Garg, S. Garg, L. J. D. Zaneveld, and A. K. Singla,
“Chemistry and pharmacology of the Citrus bioﬂavonoid
hesperidin,”PhytotherapyResearch,vol.15,no.8,pp.655–669,
2001.
[41] S. J. Hosseinimehr, A. Mahmoudzadeh, A. Ahmadi, S.
Mohamadifar, and S. Akhlaghpoor, “Radioprotective eﬀects
of hesperidin against genotoxicity induced by γ-irradiation in
humanlymphocytes,”Mutagenesis,vol.24,no.3,pp. 233–235,
2009.